Publications
NK Cells
Publication Date: March 24, 2020
Intratumoral injection of the NK-92 cell line was well tolerated and produced a local tumor response in a child with relapsed, refractory Ewing sarcoma. A 9-year-old boy with metastatic relapse, unresponsive to salvage chemotherapy and radiotherapy, received three injections on alternate days into a bulky facial mass, using NK-92 cells expanded under GMP conditions in a G-Rex® system and irradiated with 10 Gy. The total dose was 6 × 10^8 cells. Apart from brief local swelling, no complications occurred. After two cycles of vincristine, topotecan and cyclophosphamide, the facial mass regressed by about 4 cm in every dimension at week 12, whereas the pelvic mass stayed stable and new metast…
Publications
CAR T Cells, TIL Cells
G-Rex®100
Publication Date: March 8, 2020
In-house production of CD19 CAR-T cells at a single center produced fresh, non-cryopreserved infusion products in 9 to 10 days, with 99% manufacturing success, and cells from ALL patients outperformed those from NHL patients. Of 93 enrolled patients with relapsed or refractory B-cell malignancies, 91 products were made in parallel with one platform. ALL-derived cells expanded 28.7-fold by day 10 versus 17.8-fold for NHL, and contained more CAR-T cells (73.5% vs 62.6%) and more naïve CAR-T cells (60.5% vs 41.2%). Younger age improved expansion. The target dose of 1×10e6 CAR-T/kg was reached in 97% of patients; response rates were 84% in ALL and 62% in NHL.
Publications
VST Cells
Publication Date: February 25, 2020
A 14-day expansion process using pp65 peptide-pulsed autologous monocyte-derived dendritic cells generated a cytomegalovirus-specific T cell product from healthy seropositive donors that is amenable to cGMP transfer. Thawed PBMC were seeded with the dendritic cells at a 1:10 ratio in G-Rex® devices and cultured with IL-2, IL-7, IL-15 and anti-CD3/anti-CD28 antibodies. Nine batches gave a median of 43.3E+06 cells (range 4.5E+06 to 100.1E+06) from 1E+06 PBMC seeded. The product contained both CD4+ and CD8+ T cells, and IFN-γ+ CD3+ cells expanded at least 98.89-fold. Cells lysed pp65-pulsed autologous blasts, and alloreactive lysis of non-pulsed allogeneic blasts stayed below 5%.
Publications
TIL Cells
G-Rex®6 Well Plate
Publication Date: January 13, 2020
An oncolytic adenovirus armed with TNFa and IL-2 reshaped the immunosuppressive ovarian tumor microenvironment and strengthened tumor-infiltrating lymphocyte (TIL) reactivity in patient-derived samples. Ex vivo tumor cultures from patients with advanced ovarian cancer treated with Ad5/3-E2F-D24-hTNFa-IRES-hIL2 (TILT-123) showed a pooled proinflammatory-to-suppressive cytokine ratio of 2713.42 on day 6+, against about 2.1 for the unarmed virus and 1.0 for vehicle. When autologous expanded TILs were added to T-cell-depleted tumor cultures pretreated with the armed virus, antitumor reactivity, measured as IFNg, was enhanced in five of six samples. Reactivity was linked to CD4+ TILs and occur…
Publications
CAR T Cells
G-Rex®100M-CS, G-Rex®500M-CS
Publication Date: January 1, 2020
WuXi Advanced Therapies developed a closed, modular CAR-T manufacturing platform with two expansion strategies matched to dose: one step for under 10 billion total viable cells and two steps for more than 10 billion. T cells are isolated by magnetic selection on the CliniMACS Prodigy with about 60% CD3+ recovery. In G-Rex® 100M-CS flasks, one-step expansion gave 2-3 × 10^9 viable cells per flask in 9 days, and the two-step route gave about 6 × 10^9 per flask in 12 days, with viability above 85% and 90% respectively. Closed concentration, wash and formulation kept more than 70% recovery and viability. Final products contained 40-60% naive and central memory T cells.
Publications
Treg Cells
G-Rex®6M Well Plate
Publication Date: January 1, 2020
Cloudz Treg CD3/CD28, a particle-based activation reagent from Bio-Techne, expanded regulatory T cells from CD4+ cells at a performance comparable to two market suppliers. A 75 µL dose gave similar numbers and percentages of CD4+/CD25+/FoxP3+ cells after 9 days in ExCellerate T Cell Media with 10% fetal bovine serum and IL-2. Fold expansion with Cloudz reached 1663 in FBS, 1762 in 5% human serum and 1779 in 10% human serum, versus 1303, 1211 and 1521 for Supplier 1; the two were close with 5% Immune SR (761 versus 765). Serum-free medium lowered expansion for all activators, while purity stayed similar. In G-Rex®6M plates, tested across two donors, Cloudz-expanded Treg numbers were higher…
Publications
CAR T Cells, T-Cells, TIL Cells
Publication Date: December 3, 2019
Cell-based artificial antigen presenting cells (aAPCs) made from K562 cells expressing anti-CD3, anti-CD28 and CD137L expanded human T cells more effectively than antibody-coated beads. In healthy donor T cells cultured for 14 days in G-Rex® flasks, mean CD3 T-cell fold expansion was 348 with aAPCs versus 106 with CD3/28/137L beads, and in bone marrow T cells from AML patients it was 344 versus 114. Tumor infiltrating lymphocytes activated with CD137L-bearing aAPCs showed lower PD-1 and CTLA-4 than those with CD3/28 aAPCs. Adding a heparin binding domain let aAPCs support CAR retroviral transduction, and a scaled-up CD33 CAR T-cell run reached 2 × 10^8 cells with cytotoxicity comparable t…
Publications
CAR T Cells
G-Rex®100M-CS, G-Rex®6 Well Plate, G-Rex®6M Well Plate
Publication Date: December 1, 2019
Activation, retroviral transduction and expansion of T cells can be carried out in one closed G-Rex® bioreactor, using Vectofusin-1 to transduce cells in suspension instead of RetroNectin-coated bags. Against a parallel bag process, the G-Rex®100MCS process activated cells in 40 mL on day 0, added virus at MOI 5 on day 2, filled to 1 L on day 3, and harvested on day 11. It gave 2.8 ± 0.4 × 10^9 total viable cells versus 4.2 ± 1.0 × 10^8 in bags, and 55 ± 7% transduction versus 73 ± 7% (not significant), with similar phenotype and cytokine function. Estimated material cost, based on list prices, was about 38% lower.
Publications
CAR T Cells, CD34 Cells
Publication Date: November 26, 2019
Adapting HEK293T cells to suspension growth in commercial serum-free medium yielded SJ293TS cells, which produce lentiviral vectors at titers comparable to adherent HEK293T cells while using half the plasmid DNA. In the first 1-L comparisons, HEK293T titers were 1.4- to 2-fold higher, but in a later 1-L comparison SJ293TS gave 1.8-fold more vector than HEK293T cells in Cell Factory systems. Purifying 138 one-liter preparations recovered 55% ± 14% of transducing units, about twice historical adherent yields of 16% to 33%. The line produced vector stably over 4 months of culture, and its vectors efficiently transduced healthy-donor T cells and CD34+ cells. With BaEV-R-less glycoprotein, SJ2…
Publications
γδ T
Publication Date: November 22, 2019
Polyclonal γδ T cells with a predominant memory Vδ1 phenotype can be expanded from healthy-donor blood using irradiated K562-based artificial antigen-presenting cells, giving a candidate off-the-shelf product for cancer and viral targets. Cells stimulated with aAPCs expressing CD86, 41BBL, CD40L and CMV pp65 expanded 313 ± 70-fold by day 28, against 16 ± 10-fold with wild-type aAPCs. The products lysed Daudi cells, almost completely eliminated primary leukaemia blasts, degranulated against solid tumour lines and could be armed with a GD2-specific CAR. In Daudi-bearing NSG mice, three infusions of 25 × 10^6 γδ cells gave better survival than αβ T cells without graft-versus-host signs. A cl…
Publications
TIL Cells
Publication Date: November 20, 2019
Lifileucel, a cryopreserved autologous tumor-infiltrating lymphocyte product, produced objective responses in 40.5% of 42 metastatic melanoma patients whose best response to their first anti-PD-1/L1 therapy was progressive disease. These patients were enrolled in cohort 2 of the ongoing phase 2 C-144-01 trial (NCT02360579) and had undergone resection to generate their TIL. Across the full cohort of 66 patients, investigator-assessed ORR was 36.4% by RECIST v1.1. Median duration of response had not been reached at a median follow-up of 12.0 months, and 71% of responders remained on study. Grade 3 or higher treatment-emergent adverse events occurred in 97.6% of patients, and two had grade 5…
Publications
CAR T Cells
Publication Date: November 19, 2019
Cas9 base editors can knock out several genes at once in primary human T cells without the double-strand breaks that nuclease editing causes. The team targeted TRAC, B2M and PDCD1 by disrupting splice sites. Switching from first-generation BE4 mRNA to codon-optimized BE4 mRNA raised triple-knockout cells from 21.9% to 86.6% at 1.5 µg and 89.57% at 4 µg. Translocations between the target loci were virtually undetectable, whereas SpCas9 nuclease produced them, with TRAC-B2M reaching 2.04%. Base-edited T cells kept cytokine production, and CD19 CAR versions killed PD-L1-positive Raji targets as well as PD-L1-negative ones. Expansion was also better than after SpCas9 editing.
No manuscripts match your filters.